Why Licensing A Dual-Mechanism Anti-IgE Antibody Could Be A Major Opportunity For Cue Biopharma

Cue licensed CUE-221, a dual-mechanism anti-IgE antibody. A controlled Phase 2 in CSU in mainland China is expected to read out in H2 2026, after which Cue plans a global Phase 2b in food allergy.